RE:NASDAQ ListingIf a deal for xB3-001 is worth only a share price of 26¢, an addition of 9¢ to today's close, then there will never be any real value for xB3 and Bioasis.
My guess is that Ladenburg Thalmann is demanding, to the extent they can demand, that no move to Nasdaq can happen without a substantial storyboard, meaning substantial news before, during and after the move to Nasdaq. I agree with KayakerBC, news may come from xB3-001, but it could also come from xB3-004, xB3-progranulin, Chiesi LSD IND submission, maybe even IND approval, EGF1 clinical trial news plus a surprise or two from the many partners and collaborators that Bioasis has. (Oxyrane, Aposense, Neuramedy, Daiichi Sankyo, Janssen, etc)
That makes it really hard to discuss the terms for a Nasdaq listing. Bioasis may have enough deal flow to end up with a lot of cash and a good share price, leaving Bioasis substantially able to qualify for a Nasdaq listing, maybe a complete listing, with no wonky rollbacks and half vast TSXV/Nasdaq co-listing.
Of course, there is a possibility of a pharma taking an equity position in Bioasis, something that could substantially change Bioasis's share structure and satisfy some Nasdaq cash and share price listing requirements..
And then there may be a merger option with a company already on Nasdaq where Bioasis shareholders could end up with a nice piece of the resulting entity.
There are so many unknowns and possibilities that thinking about it at this point is almost pointless.
At the end of the day, DrDR, Ladenburg Thalmann and probably a whole big bunch of others know exactly how it's going to get done and are sitting there laughing at them dumb Stockhouse posters who don't know nothin' about nothin'. Some people are at the table, some are in the room, and the rest are outside. We're outside.
jd